Decreased parasite burden and altered host response in children with sickle cell anemia and severe anemia with malaria

Tracking no: ADV-2021-004704R2

Ryan Henrici (London School of Hygiene & Tropical Medicine, United Kingdom) Casey Sautter (University of California San Francisco, United States) Caitlin Bond (Indiana University School of Medicine, United States) Robert Opoka (College of Health Sciences, Makerere University, Uganda) Ruth Namazzi (College of Health Sciences, Makerere University, Uganda) Dibyadyuti Datta (Indiana University School of Medicine, United States) Russell Ware (Cincinnati Children's Hospital Medical Center, United States) Andrea Conroy (Indiana University School of Medicine, United States) Chandy John (Indiana University, United States)

Abstract:
Plasmodium falciparum malaria causes morbidity and mortality in African children with sickle cell anemia (SCA), but comparisons of host responses to P. falciparum between children with SCA (HbSS) and HbAA are limited. We assessed parasite biomass and plasma markers of inflammation and endothelial activation in children with HbAA (n=208) or HbSS (n=22) who presented with severe anemia and P. falciparum parasitemia to Mulago Hospital in Kampala, Uganda. Genotyping was performed at study completion. No child had known SCA at enrollment. Children with HbSS did not differ from children with HbAA in peripheral parasite density, but had significantly lower sequestered parasite biomass. Children with HbSS had greater leukocytosis but significantly lower concentrations of several plasma inflammatory cytokines, including TNF-α. In contrast, children with HbSS had 3-fold greater concentrations of angiopoietin-2 (Angpt-2), a marker of endothelial dysregulation associated with mortality in severe malaria. Lower TNF-α concentrations were associated with increased risk of post-discharge mortality or readmission, while higher Angpt-2 concentrations were associated with increased risk of recurrent clinical malaria. Children with SCA have decreased parasite sequestration and inflammation but increased endothelial dysregulation during severe anemia with P. falciparum parasitemia, which may ameliorate acute infectious complications but predispose to harmful long-term sequelae.

Conflict of interest: No COI declared

COI notes:

Preprint server: No;

Author contributions and disclosures: RCH performed statistical analysis, literature review, and wrote the first draft of the manuscript. CB performed Cox and interaction analyses. DD and ALC assisted the design of the study. ROO, RN, CCJ were all involved in the administration and conduct of the clinical trial upon which this study is based. All authors commented on and approved the final version of this manuscript.

Non-author contributions and disclosures: No;

Agreement to Share Publication-Related Data and Data Sharing Statement: Email to corresponding author

Clinical trial registration information (if any):
Decreased parasite burden and altered host response in children with sickle cell anemia and severe anemia with malaria

Authors: Ryan C. Henrici1,2, Casey L. Sautter3, Caitlin Bond4, Robert O. Opoka5, Ruth Namazzi5, Dibyadyuti Datta2, Russell E. Ware6, Andrea L. Conroy4, Chandy C. John4

Affiliations

1. Perelman School of Medicine Center for Global Health, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America
2. Department of Pathogen Infection Biology, London School of Hygiene & Tropical Medicine, London, United Kingdom
3. Health, Equity, Action, Leadership (HEAL) Initiative, Division of Hospital Medicine, University of California – San Francisco, San Francisco, California, United States of America
4. Ryan White Center for Pediatric Infectious Diseases and Global Health, Indiana University School of Medicine, Indianapolis, Indiana, United States of America
5. Department of Paediatric and Child Health, Makerere University School of Medicine, Kampala, Uganda
6. Division of Hematology and Global Health Center, Cincinnati Children’s Hospital Medical Center, and Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, United States of America

Running title: SCA curbs inflammatory response to severe malaria

Corresponding Author:

Chandy C. John, MD, MS
Ryan White Professor of Pediatrics
Professor of Medicine, Microbiology and Immunology
Director, Ryan White Center for Pediatric Infectious Diseases and Global Health

T: 317 274 8940
E: chjohn@iu.edu

Word Count: 3936

Abstract Word Count: 199
**Key Points**

1. Children with SCA have decreased parasite burden and inflammation but increased endothelial dysregulation during severe anemia with malaria.

2. Host response to malaria with severe anemia in children with SCA may reduce acute disease severity but increase risk of long-term sequelae.

**Abstract**

*Plasmodium falciparum* malaria causes morbidity and mortality in African children with sickle cell anemia (SCA), but comparisons of host responses to *P. falciparum* between children with SCA (HbSS) and HbAA are limited. We assessed parasite biomass and plasma markers of inflammation and endothelial activation in children with HbAA (n=208) or HbSS (n=22) who presented with severe anemia and *P. falciparum* parasitemia to Mulago Hospital in Kampala, Uganda. Genotyping was performed at study completion. No child had known SCA at enrollment. Children with HbSS did not differ from children with HbAA in peripheral parasite density, but had significantly lower sequestered parasite biomass. Children with HbSS had greater leukocytosis but significantly lower concentrations of several plasma inflammatory cytokines, including TNF-α. In contrast, children with HbSS had 3-fold greater concentrations of angiopoietin-2 (Angpt-2), a marker of endothelial dysregulation associated with mortality in severe malaria. Lower TNF-α concentrations were associated with increased risk of post-discharge mortality or readmission, while higher Angpt-2 concentrations were associated with increased risk of recurrent clinical malaria. Children with SCA have decreased parasite sequestration and inflammation but increased endothelial dysregulation during severe anemia with *P. falciparum* parasitemia, which may ameliorate acute infectious complications but predispose to harmful long-term sequelae.
Introduction

Sickle cell anemia (SCA) affects 25 million people worldwide, including more than 300,000 newborn children each year. Most of these children live in sub-Saharan Africa. SCA is highly prevalent in sub-Saharan Africa because of the protective effect of HbAS, the heterozygous sickle gene mutation, against malaria, particularly severe malaria. Thus, SCA primarily affects African regions with historically high malaria transmission.

Malaria is considered a major cause of morbidity and death in African children with SCA, but data on the incidence of malaria and of deaths from malaria in children with SCA are limited. Two studies with small numbers of children with SCA and severe malaria in Kenya and Tanzania (n=5 and n=21, respectively) suggested that children with SCA have a high mortality rate with severe malaria. However, a recent systematic review found children with HbSS do not have an increased risk of developing uncomplicated malaria, and recent studies of children with SCA and severe malaria in Kenya (38 children with severe malarial anemia (SMA) and Uganda (5 children with severe malaria and separately 22 children with SMA) all showed no mortality.

The controversy surrounding risk of mortality in children with HbSS and severe malaria underscores how little is currently known of the pathogenesis and host responses in severe malaria in individuals with HbSS compared to HbAA. Specific factors associated with severe disease and mortality in severe malaria, including the pro-inflammatory cytokine TNFα and components of the angiopoietin (Angpt)-Tie-2 system, are also associated with clinical severity in SCA. However, there have been no studies to date comparing these and other host responses in children with HbSS versus HbAA during episodes of severe anemia with P. falciparum parasitemia, or how the host response may alter parasite sequestration and density. In the present study, we assessed differences in children with HbSS vs. HbAA in parasite biomass and markers of inflammation and endothelial activation during severe anemia with P. falciparum parasitemia, to better determine how SCA affects the host response to P. falciparum during severe malaria.
Methods

Study participants. The study was performed at Mulago Hospital, Kampala, Uganda. Participants were enrolled in a study assessing neurodevelopmental impairment in severe malaria, conducted from November 2008 to December 2013. Children 18 months – 12 years of age with cerebral malaria (CM) or SMA meeting study criteria were enrolled from the Acute Care Unit at Mulago Hospital.

Community children were recruited from the extended family or nearby neighborhood of children with CM or SMA. A total of 267 children with CM, 232 children with SMA and 216 community children with no acute illness were enrolled in the study. The age, sex and presence of HbAA, HbAS, or HbSS in each group is summarized in Supplemental Table 1. Enrollment criteria for children with CM and the community children were previously published. In this study, we focus on the children with SMA, because 22 children with SMA had HbSS compared to 1 with CM and no community children. SMA was defined per the Uganda Ministry of Health National Guidelines as P. falciparum parasitemia on blood smear in a child with hemoglobin level ≤ 5.0 g/dL. Children with SMA were excluded if they had impaired consciousness at the time of examination, other clinical evidence of CNS disease, or if they had >1 seizure before admission. Exclusion criteria for all groups included known chronic illness requiring medical care, developmental delay, prior history of coma, head trauma or cerebral palsy, or prior hospitalization for malnutrition. 25 children were excluded for prior diagnosis of SCA at the time of admission for SMA or CM.

Clinical management. Children were managed according to Ugandan Ministry of Health treatment guidelines for malaria, which at time included intravenous quinine or artesunate followed by oral quinine or artemether-lumefantrine. All children with SMA received a blood transfusion (20ml/kg of whole blood or 10ml/kg of packed red blood cells).

HbS testing: Beta globin genotyping was performed on stored samples after study completion. Genomic DNA was isolated from whole blood samples using the DNeasy Blood and tissue kit (Qiagen, Valencia, CA). The locus of interest was amplified using specific primers. Children with
HbSS were referred to the Mulago Hospital Sickle Cell Clinic, where HbSS was confirmed by hemoglobin electrophoresis.

Blood chemistries and immunoassays. *Plasmodium* infection was diagnosed by microscopy on Giemsa-stained peripheral blood smears; parasitemia was counted using standard procedures. Blood chemistries were performed by the Advanced Research and Diagnostic Lab at the University of Minnesota. Complete blood counts were performed by the clinical laboratory at Mulago Hospital. Biomarkers were detected using enzyme-linked immunosorbent assays (ELISA) using plasma isolated from whole blood collected in EDTA or lithium-heparin tubes. Prior to analysis, samples were stored at -80°C. Plasma *P. falciparum* histidine-rich protein-2 (PfHRP-2) was quantitated using the Malaria Ag CELISA (Cellabs, Brookvale, Australia), total parasite biomass was estimated as $P_{tot} = 7.3 \times 10^{13}$ parasites/µL x 0.08 L/kg x body weight (blood volume), and sequestered biomass was calculated as $P_{seq} = P_{tot} - P_{circ}$ as previously described.²⁸ Plasma TNFα and IL-6 concentrations were determined using a 2-plex assay from EMDMillipore (Billericia, MA). All other cytokines were measured using a Bio-Plex Human Cytokine 17-plex Assay (BioRad, Hercules, CA). von Willebrand Factor (vWF) was measured using the READDS VWF:Ag ELISA (Corgenix Inc., Broomfield, CO) and expressed as a relative percentage concentration as derived from reference plasma. Angiopoietin (Angpt)-1 and Angpt-2 were detected in plasma diluted 1:5 using DuoSet ELISA (R&D Systems, Minneapolis, MN). Soluble adhesins (sICAM-1, sVCAM-1, P-selectin, sE-Selectin) were measured by cytometric bead assay (R&D Systems, Minneapolis, MN) using plasma diluted 1:300. sEPCR was detected via Asserachrom immunoassay against the sEPCR PC binding site (Stago, France). C-reactive protein (CRP) and alpha-1-acid glycoprotein (AGP) were measured by Milliplex MAP human cytokine magnetic bead kit (EMDMillipore) and Quantikine ELISA (R&D Systems) respectively. Plasma asymmetric dimethylarginine (ADMA) was measured by ELISA (DLD Diagnostika GmbH, Hamburg, Germany), L-arginine by Hitachi Amino Acid Analyser (Hitachi High-Tech Co., Nashville, TN), and total nitric oxide measurements by fluorimetric analysis (Calbiochem,
San Diego, CA) via treatment with nitrate reductase and fluorescence conversion and detection of total nitrite (total NO) via 2,3-diaminonaphthalene.

**Statistical Analysis.** Statistical analysis was performed in STATA 15 (Stata Corporation, College Station, TX). Categorical variables, continuous parametric, and non-parametric continuous variables were compared with the χ² test, Student’s T test, and Wilcoxon Rank-Sum test, respectively. Linear regression models were used to adjust for age, with log-transformation (base 10) of variables not normally distributed. False discovery rate (FDR) was set at 0.05. The relationship between Angpt-2 or TNF-α and risk of readmission or death or risk of clinical malaria was analyzed using Cox proportional hazards regression, with adjustment for age and hemoglobin genotype.

**Ethical review.** Written informed consent was obtained from parents or guardians of study participants. Institutional Review Boards for human studies at Makerere University and the University of Minnesota granted ethical approval for the study. Additional regulatory approval was obtained from the Uganda National Council of Science and Technology.

**Results**

**Demographic and clinical characteristics.** Among the 232 children admitted for Uganda Ministry of Health-defined SMA (severe anemia [hemoglobin ≤5 g/dL], with *P. falciparum* parasitemia) who had samples available for genotyping, 208 children had HbAA and 22 had the SC A HbSS genotype. Two children with SMA had HbAS and were omitted from this analysis. Demographic characteristics are summarised in Table 1. Children with HbSS were significantly older than children with HbAA, so all comparisons were adjusted for age. Clinical characteristics of children with HbSS and HbAA were similar (Table 1). During admission, there were no deaths in the 22 children with HbSS, and one death in the 208 children with HbAA. No child with HbSS was taking hydroxyurea.

**Clinical laboratory values.** Hemoglobin concentrations were similar in children with SMA regardless of hemoglobin genotype (Table 2). The white blood cell count (WBC) in children with
HbSS was almost 3-fold higher than in HbAA (mean WBC (standard deviation) 32.5x10^3/µl (16.0) compared to 12.9x10^3/µl (8.2), P <0.001). Other clinical lab differences included increased MCV and RDW; higher platelet counts, plasma bilirubin and albumin; and lower LDH, creatinine and BUN concentrations in children with HbSS compared to children with HbAA (Table 2). Among 18 children with SCA who had blood cultures drawn during admission, one (5.6%) had concomitant bacteremia, compared to 22 of 178 (12.3%) children without SCA. No child with SCA had evidence of helminthic infection, whereas 10 of 208 (4.8%) children without SCA did. HIV was detected in 6 of 205 (2.9%) children without SCA and no child with SCA (Table 2).

Risk of post-discharge clinical malaria, readmission or death. There was no difference in the risks of post-discharge clinical malaria or post-discharge readmission or death between children with HbSS vs. HbAA (HR [95% CI], malaria: 1.13 [0.60, 2.10]; readmission or death: 1.65 [0.78, 3.47]).

Peripheral parasite density and estimated total, circulating and sequestered parasite biomass. Children with HbSS had similar levels of peripheral parasitemia and estimated circulating *P. falciparum* biomass to children with HbAA, but lower *P. falciparum* HRP-2 concentrations (197 vs. 1051 ng/mL, P < 0.001) and estimated total (238x10^9 vs 835x10^9, P < 0.001) and sequestered (130x10^9 vs 731x10^9, P < 0.001) parasite biomass (Table 2, Supplemental Figure 1). Hemoglobin concentration inversely correlated with total parasite biomass (log 10-transformed) in children with HbAA (β = 0.33 [95% CI: 0.18, 0.48]; P < 0.001), but was unrelated to total parasite biomass in children with HbSS (β = 0.05 [95% CI: -0.12, 0.22]; P = 0.5).

Cytokines and inflammatory cytokines. Although children with SCA presented with greater leukocytosis than children with HbAA, children with SCA had significantly lower levels of the inflammatory biomarkers α-1-acid glycoprotein (AGP) (1350 v 2128 mcg/mL, P < 0.001) and C-reactive protein (25.0 v 44.0 mg/dL, P < 0.001) than children with HbAA (Table 2). Similarly, concentrations of the immune activator tumor necrosis factor (TNF)-α and the pro-inflammatory chemokines monocyte chemoattract protein (MCP)-1 and macrophage inflammatory protein (MIP)-1β...
were lower in children with HbSS compared to children with HbAA (Table 3). PfHRP-2, a marker of total parasite biomass, correlated strongly with CRP concentrations ($\beta = 3.14$ [95% CI: 1.94, 4.34]; $P < 0.001$), as well as the three pro-inflammatory cytokines and chemokines (TNF$\alpha$, MCP-1, MIP-1$\beta$, all $P < 0.001$).

**Markers of endothelial activation and angiogenesis.** Endothelial activation occurs in SCA and severe malaria.$^{1,19,23,29-33}$ Recent data have implicated the Angpt-Tie-2 system in the pathogenesis of SCA and severe malaria, where elevated Angpt-2 and decreased Angpt-1 correlate with disease severity.$^{17-22}$ We quantitated levels of these and other biomarkers of endothelial activation as well as angiogenic cytokines vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) in this study population (Table 2). Median Angpt-2 was 3-fold higher in the children with HbSS compared to HbAA (5.0 vs 1.7 ng/mL, $P = 0.01$, Table 2). Median plasma concentrations of soluble endothelial protein C receptor (sEPCR), the soluble form of PfEMP1-binding receptors important in microvascular sequestration and the pathogenesis of cerebral malaria$^{30,34,35}$, were lower in children with HbSS (adjusted $P = 0.05$).

In addition to VEGF, nitric oxide (NO) responds to tissue hypoxia, inducing vasodilation and angiogenesis.$^{36-39}$ NO production requires L-arginine, and ADMA is a negative regulator of nitric oxide production. The ratio of L-arginine and ADMA reflects NO homeostasis.$^{40}$ Lower L-arginine and higher ADMA levels in children with HbSS would be expected with the hypoxia and tissue damage caused by vaso-occlusion in SCA. Children with HbSS had lower L-arginine and higher ADMA concentrations (lower L-arginine:ADMA ratio) than children with HbAA (Table 3), reflecting dysregulated NO homeostasis in response to *P. falciparum* infection in children with severe malaria and SCA.

**Association of endothelial and pro-inflammatory factors with long-term outcomes.** Severe anemia confers increased risk of death or readmission after discharge$^{41}$, and children with SMA are at risk of readmission or uncomplicated malaria after discharge.$^{42,43}$ Given the differences in TNF$\alpha$,
Angpt-2, and L-arginine:ADMA ratios noted here among children with SMA, and previous data linking these factors with adverse sequelae including death\textsuperscript{44-47}, we assessed associations between these factors and post-discharge death or readmission or uncomplicated malaria incidence during the 24 month follow-up period of the study (Table 4, Supplemental Tables 2, 3). Contrary to our expectations, higher TNFα concentrations during SMA were associated with a lower risk of post-discharge death or readmission (HR 0.55 [95% CI: 0.36-0.83], P = 0.004). Angpt-2 concentrations, also elevated in the children with SCA, were not significantly associated with altered risk for readmission or death after discharge (Table 4). However, Angpt-2 concentrations were associated with significantly increased risk of uncomplicated malaria (HR 2.03 [95% CI: 1.14-3.59], P = 0.016).

There was no interaction between hemoglobin genotype and TNFα or Angpt-2 concentration on the risk of post-discharge uncomplicated malaria, readmission, or mortality.

**Discussion**

Understanding differences in pathogenesis and host responses to *P. falciparum* is critical to determining how malaria affects children with SCA and may provide insights into how to prevent acute and long-term complications of malaria infection in children with SCA. In the present study, children with severe anemia (hemoglobin ≤5 g/dL) and *P. falciparum* parasitemia differed in their level of parasite sequestration, pro-inflammatory response and level of endothelial cell dysfunction according to whether they had HbSS or HbAA. Children with severe anemia and *P. falciparum* parasitemia were enrolled and classified in the study as having severe malarial anemia based on Uganda Ministry of Health criteria. However, since we cannot completely exclude other causes of anemia in children with SCA, we have termed the clinical condition “severe anemia with *P. falciparum* parasitemia” rather than “severe malarial anemia.”

Among children with severe anemia and *P. falciparum* parasitemia, and without SCA had similar clinical characteristics during severe malaria, but children with SCA broadly attenuated parasite biomass and inflammatory mediators. Children with SCA had higher WBC counts compared to children without SCA, but concentrations of C-reactive protein\textsuperscript{48,49} and multiple pro-inflammatory cytokines, including TNFα, were significantly decreased. Pronounced leukocytosis and
thrombocytosis are known features of steady state SCA, as seen in the NOHARM trial also conducted at Mulago Hospital, and thus do not directly reflect the inflammatory response due to malaria.\textsuperscript{15} Similarly, Angpt-2 was elevated and Arg:ADMA ratio lower in children with SCA, also features of steady state SCA that may be exacerbated by malarial infection. Across the cohort as a whole, decreased TNF\textgreek{a} was associated with increased risk of post-admission readmission or death, while increased Angpt-2 was associated with increased risk of subsequent uncomplicated clinical malaria. The findings suggest two possibilities: children with HbSS may express symptoms of illness at a lower parasite biomass and with less inflammation than children with HbAA, or that SCA-related mechanisms, still not fully characterized, may lead to attenuation of parasite sequestration and sequestration-driven inflammation in children with SCA compared to children without SCA. The data also hint at potential long-term consequences from severe malaria, if the associated endothelial and NO dysregulation persist after the malaria episode.

The reduction in sequestered but not circulating \textit{P. falciparum} biomass and concomitant decrease in pro-inflammatory factors in children with SCA during severe anemia with \textit{P. falciparum} parasitemia was surprising. A number of studies suggest that peripheral \textit{P. falciparum} density is lower in children with SCA than in children with HbAA.\textsuperscript{5,11,14,50–52} In three studies describing their calculations, each applied a standard value (ranging from an arbitrary 8x10\textsuperscript{3}/\mu l to the observed population mean WBC, 14.8x10\textsuperscript{3}/\mu l) to all patients in the cohort.\textsuperscript{11,14,50} However, during SMA, children with SCA have higher and more variable WBC counts (mean (SD) 32.5x10\textsuperscript{3}/\mu L (16.0) in the present study). When we used a standard WBC count for all children, peripheral parasite density was lower in children with SCA, but when we used individual WBC determined on the day of diagnosis, peripheral parasite density did not differ significantly. Thus, measurement and incorporation of exact WBC counts into parasitaemia calculations on a per-participant basis is essential.

Insights from studies of HbAC trait and HbC disease, hemoglobinopathies caused by a similar mutation in the \beta-globin chain encoding E6K (HbC) rather than E6V (HbS), may shed light on our novel observations in children with HbSS/SCA.\textsuperscript{7,53–55} In particular, HbC expression also provides
substantial protection from severe malarial infection (HbCC greater than HbAC), and the mechanism of this protection stems from impaired PfEMP1 export and reduced cytoadherence of parasitized heterozygous HbAC and homozygous HbCC red cells. Impaired PfEMP1 export in these experiments impairs rosetting, the clinically-important process of clumping of infected RBCs in the microvasculature, with predicted reductions in inflammation. HbCC disease has thus been associated with protection from cerebral malaria. Subsequent studies with HbS-containing red cells found a similar reduction in cytoadherence in HbSS compared to HbAA cells in vitro, suggesting commonalities between HbSS and HbCC disease on a cellular level. Molecular studies link this abnormal EMP1 display to inhibition of RBC actin remodeling by HbS oxidation products, which disrupts Mauer’s Cleft biogenesis. Interestingly, heterozygous HbAS individuals may not exhibit the same protection from sequestration, though this remains understudied in vivo. Reduced PfEMP-1 export in individuals with HbSS could explain decreased sequestration in children with SCA, and decreased binding of infected RBC to endothelial cells may reduce the likelihood of vaso-occlusive crisis during the malaria episode in these children.

Impaired cytoadherence demonstrated in these studies and HbS-mediated anti-plasmodial cytotoxicity demonstrated by others may underlie the unexpected molecular and parasitologic response to severe malaria observed here in children with SCA. During the intraerythrocytic cycle, some sequestered parasites are likely killed in the hypoxic environment of the HbSS red cell and venous microvasculature, reducing the overall parasite burden, while others slip back into circulation due to impaired cytoadherence, reducing sequestered biomass and normalizing the peripheral parasitemia between patients with and without SCA. Increased phagocytosis of sickled, parasitized red cells in children with SCA may also contribute to globally reduced parasitaemia.

In the present study cohort, HbSS was a strong risk factor for severe anemia with P. falciparum parasitemia, with a prevalence of 9.6%, while HbSS was not present in a parallel cohort of asymptomatic children in the same community. Children with HbSS have baseline anemia, so are at higher risk of developing severe anemia with P. falciparum parasitemia during malarial infection.
Thus, in SCA, while the decrease in parasite sequestration does not protect from malaria manifested as severe anemia, it may have contributed to the lack of mortality or signs of additional disease severity in these children. For example, decreased sequestration may explain why in other studies, children SCA experience fewer neurovascular complications of severe malaria such as convulsions and impaired consciousness. Importantly, although plasma HRP-2 allows mathematical calculation of sequestered biomass, some isolates display variation in HRP-2 secretion, and HRP-2 half-life, related to acquired immunity, may vary by patient, so parasite biomass must be viewed as a crude estimate in any individual study participant.

Additionally, children with SCA may be protected from mortality during an acute episode of SMA by broadly reduced inflammation, which is intimately linked with parasite sequestration. Specifically, the interaction of ICAM-1 and PfEMP1 is a major molecular event driving sequestration and major pro-inflammatory event that drives the release of TNFα, which triggers further luminal display of ICAM-1 on endothelial cells. In our cohort, children with SCA had significantly lower levels of TNFα and trended towards lower concentrations of sEPCR, another substrate for PfEMP1 binding. Other vascular adhesins ICAM-1, VCAM-1, E- and P-selectins were not significantly increased or decreased in children with SCA, despite markedly elevated Angpt-2, suggesting a decoupling of the acute inflammatory response and chronic Angpt-2 elevation. Given chronic inflammation and hemolysis during steady state in children with SCA, chronically upregulated compensatory anti-inflammatory mechanisms (e.g. free heme induction of heme oxygenase-1) may impair the endothelial and systemic inflammatory response to acute infection. It is puzzling that chronic endothelial activation does not increase parasite sequestration, suggesting a greater role for parasite-specific factors in this observation. Overall, these significant reductions in inflammatory and endovascular markers in children with SCA and SMA suggest an important modification of the typical aggressive inflammatory host response to \textit{P. falciparum}, which has not previously been described.
Children with SCA in this study also had increased Angpt-2 and a low L-arginine:ADMA ratio, which have been previously associated with disease severity and risk of complications, including mortality, in adults and children. In our cohort, lower levels of TNFα were associated with increased risk of all cause post-discharge mortality or readmission, while increased levels of Angpt-2 were associated with increase uncomplicated malaria incidence post-discharge. Children with SCA experienced both of these host responses during severe anemia with *P. falciparum* parasitemia. Additional studies are required to further examine the long-term effects of the attenuated inflammatory response to severe anemia with *P. falciparum* parasitemia that we note here in children with SCA on the risks of reinfection, readmission, and mortality, as this single temporal risk calculation considers only a single episode of malaria, and these children experience frequent infection.

Importantly, severe anemia commonly causes hospitalization in patients with SCA, and the etiology is often multi-factorial. In this study, we defined SMA according to the Ugandan Ministry of Health guidelines, which includes any peripheral parasitemia rather than a specific parasite density threshold, as specified in the revised WHO definition. Although incidental malaria parasitemia can be seen in individuals in endemic areas, it appears likely that malaria contributed to the severe anemia in this study population. We assessed for other infection, including bacteremia, HIV infection and stool helminth infection, and found only 1 case of bacteremia among the 22 children with HbSS, with no HIV or stool helminth infections, suggesting that other infection was not a major contribution to the anemia in these children. Importantly, all SCA-SMA biomarker and biomass associations discussed here remained significant after exclusion of all of these children and application of the stringent WHO definition of SMA (Supplemental Table 5), suggesting the trends identified are not due to incidental parasitemia with concurrent severe anemia of SCA. Malnutrition can be associated with severe anemia, but the children with SCA were not chronically malnourished and had better height-for-age and weight-for-age z-scores than the children without SCA. PfHRP-2 concentrations, a measure of parasite sequestration and biomass, also correlated with inflammation, further supporting a contribution of *P. falciparum* to the disease process in these children. Children with SCA in this study
were also older than children without SCA and may have acquired greater cellular and humoral immunity to *P. falciparum* malaria. However, the associations reported are robust after correction for age and likely reflect true differences in the molecular response to severe malaria. It is possible that the children with SCA in this cohort had milder SCA than the general population of children with SCA, as they did not have a diagnosis of SCA prior to enrolment. The physiologic differences seen between children with and without SCA were nonetheless striking and highly significant. Thus, we hypothesize that the malaria-infected host is likely balancing inflammation, parasitaemia, and endovascular activation, and children with SCA may carry significant long-term risk from these maladaptive responses.

In summary, we present the first evidence that parasite sequestration and host inflammatory responses, including several pro-inflammatory cytokines and endovascular adhesins, are attenuated in children with SCA during severe anemia with *P. falciparum* parasitemia, despite profoundly elevated Angpt-2 and evidence of NO dysregulation. These results give a first window into the pathophysiology of acute severe malaria in the context of SCA and provide a basis for future studies to determine the how baseline changes in inflammation and endothelial cell function in African children with SCA may affect the risk of and response to *P. falciparum* malaria and long-term complications of SCA and malaria.

Data sharing statement

For data sharing, contact the corresponding author: chjohn@iu.edu.

Author Contributions

RCH performed statistical analysis, literature review, and wrote the first draft of the manuscript. CB performed Cox and interaction analyses. DD and ALC assisted the design of the study. ALC performed quantitative serological studies. ROO, RN, CCJ were all involved in the administration and conduct of the clinical trial upon which this study is based. CCJ, ALC, RW, and CS edited the manuscript. All authors commented on and approved the final version of this manuscript.

Acknowledgments
We thank the children and their parents who participated in this study, and the study team for their
dedicated effort in treating the children and collecting these data.

**Financial support**

This work was supported by the National Institute of Neurological Disorders and Stroke and the
Fogarty International Center (grants R01NS055349 and D43 NS078280)

**Competing Financial Interests**

The authors declare no competing financial interests.
1. Ware RE, de Montalembert M, Tshilolo L, Abboud MR. Sickle cell disease. *Lancet*. 2017;390(10091):311–323.

2. Piel FB, Hay SI, Gupta S, Weatherall DJ, Williams TN. Global Burden of Sickle Cell Anaemia in Children under Five, 2010-2050: Modelling Based on Demographics, Excess Mortality, and Interventions. *PLoS Med*. 2013;10(7):e1001484–e1001484.

3. Piel FB, Steinberg MH, Rees DC. Sickle Cell Disease. *N. Engl. J. Med*. 2017;376(16):1561–1573.

4. Piel FB, Patil AP, Howes RE, et al. Global distribution of the sickle cell gene and geographical confirmation of the malaria hypothesis. *Nat. Commun*. 2010;1(8):1–7.

5. Lopera-Mesa TM, Doumbia S, Konaté D, et al. Effect of red blood cell variants on childhood malaria in Mali: A prospective cohort study. *Lancet Haematol*. 2015;2(4):e140–e149.

6. Bunn HF. The triumph of good over evil: Protection by the sickle gene against malaria. *Blood*. 2013;121(1):20–25.

7. May J, Evans JA, Timmann C, et al. Hemoglobin variants and disease manifestations in severe falciparum malaria. *J. Am. Med. Assoc*. 2007;297(20):2220–2226.

8. Aidoo M, Terlouw DJ, Kolczak MS, et al. Protective effects of the sickle cell gene against malaria morbidity and mortality. *Lancet*. 2002;359(9314):1311–1312.

9. Williams TN, Mwangi TW, Wambua S, et al. Sickle cell trait and the risk of Plasmodium falciparum malaria and other childhood diseases. *J. Infect. Dis*. 2005;192(1):178–186.

10. Rockett KA, Clarke GM, Fitzpatrick K, et al. Reappraisal of known malaria resistance loci in a large multicenter study. *Nat. Genet*. 2014;46(11):1197–1204.

11. Makani J, Komba AN, Cox SE, et al. Malaria in patients with sickle cell anemia: Burden, risk factors, and outcome at the outpatient clinic and during hospitalization. *Blood*. 2010;115(2):215–220.

12. McCauley CF, Webb C, Makani J, et al. High mortality from Plasmodium falciparum malaria in children living with sickle cell anemia on the coast of Kenya. *Blood*. 2010;116(10):1663–1668.

13. Taylor SM, Parobek CM, Fairhurst RM. Haemoglobinopathies and the clinical epidemiology of malaria: A systematic review and meta-analysis. *Lancet Infect. Dis*. 2012;12(6):457–468.

14. Komba AN, Makani J, Sadarangani M, et al. Malaria as a cause of morbidity and mortality in children with homozygous sickle cell disease on the coast of Kenya. *Clin. Infect. Dis*. 2009;49(2):216–222.

15. Opoka RO, Ndugwa CM, Latham TS, et al. Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM): a trial for children with sickle cell anemia. *Blood*. 2017;130(24):2585–2593.

16. Opoka RO, Bangirana P, Idrro R, et al. Lack of mortality in 22 children with sickle cell anemia and severe malaria anemia. *Pediatr. Blood Cancer*. 2018;65(1):.

17. Duits AJ, Rodriguez T, Schnog JJB. Serum levels of angiogenic factors indicate a pro-angiogenic state in adults with sickle cell disease. *Br. J. Haematol*. 2006;134(1):116–119.

18. Andrawes NG, Ismail EA, Rosedly MM, et al. Angiopoietin-2 as a Marker of Retinopathy in Children and Adolescents with Sickle Cell Disease: Relation to Subclinical Atherosclerosis. *J. Pediatr. Hematol. Oncol*. 2019;41(5):361–370.

19. De Jong GM, Slager JJ, Verbon A, Van Hellemont JJ, Van Genderen PJ. Systematic
review of the role of angiopoietin-1 and angiopoietin-2 in Plasmodium species infections: biomarkers or therapeutic targets? *Malar. J.* 2016;15(1):1–12.

20. Antwi-Boasiako C, Frimpong E, Gyan B, et al. Elevated Proangiogenic Markers are Associated with Vascular Complications within Ghanaian Sickle Cell Disease Patients. *Med. Sci.* 2018;6(3):53.

21. Cruz PRS, Lira RPC, Pereira Filho SAC, et al. Increased circulating PEDF and low sICAM-1 are associated with sickle cell retinopathy. *Blood Cells. Mol. Dis.* 2015;54(1):33–37.

22. Ofori-Acquah SF, Buchanan ID, Osunkwo I, et al. Elevated circulating angiogenic progenitors and white blood cells are associated with hypoxia-inducible angiogenic growth factors in children with sickle cell disease. *Anemia.* 2012;2012:1–9.

23. Higgins SJ, Purcell LA, Silver KL, et al. Dysregulation of angiopoietin-1 plays a mechanistic role in the pathogenesis of cerebral malaria. *Sci. Transl. Med.* 2016;8(358):358ra128.

24. Bangirana P, Opoka RO, Boivin MJ, et al. Severe malarial anemia is associated with longterm neurocognitive impairment. *Clin. Infect. Dis.* 2014;59(3):336–344.

25. Uganda Clinical Guidelines: National Guidelines for Management of Common Conditions. 2016.

26. Legason ID, Pfeiffer RM, Udquim KI, et al. Evaluating the Causal Link Between Malaria Infection and Endemic Burkitt Lymphoma in Northern Uganda: A Mendelian Randomization Study. *EBioMedicine.* 2017;25:58–65.

27. Jallow M, Teo YY, Small KS, et al. Genome-wide and fine-resolution association analysis of malaria in West Africa. *Nat. Genet.* 2009;41(6):657–665.

28. Park GS, Opoka RO, Shabani E, et al. Plasmodium falciparum histidine-rich protein-2 plasma concentrations are higher in retinopathy-negative cerebral malaria than in severe malarial anemia. *Open Forum Infect. Dis.* 2017;4(3):ofx151.

29. Yeo TW, Lampah DA, Gitawat R, et al. Angiopoietin-2 is associated with decreased endothelial nitric oxide and poor clinical outcome in severe falciparum malaria. *Proc. Natl. Acad. Sci. U. S. A.* 2008;105(44):17097–17102.

30. Turner L, Lavstsen T, Berger SS, et al. Severe malaria is associated with parasite binding to endothelial protein C receptor. *Nature.* 2013;498(7455):502–505.

31. Hawkes M, Elphinstone RE, Conroy AL, Kain KC. Contrasting pediatric and adult cerebral malaria: The role of the endothelial barrier. *Virulence.* 2013;4(6):545–555.

32. Solovey A, Lin Y, Browne P, et al. Circulating Activated Endothelial Cells in Sickle Cell Anemia. *N. Engl. J. Med.* 1997;337(22):1584–1590.

33. Kucukal E, Ilich A, Key NS, Little JA, Gurkan UA. Red blood cell adhesion to heme-activated endothelial cells reflects clinical phenotype in sickle cell disease. *Am. J. Hematol.* 2018;93(8):1050–1060.

34. Tuikue Ndam N, Moussiliou A, Lavstsen T, et al. Parasites Causing Cerebral Falciparum Bind Multiple Endothelial Receptors and Express EPCR and ICAM-1-Binding PfEMP1. *J. Infect. Dis.* 2017;215(12):1918–1925.

35. Kessler A, Dankwa S, Bernabeu M, et al. Linking EPCR-Binding PfEMP1 to Brain Swelling in Pediatric Cerebral Malaria. *Cell Host Microbe.* 2017;22(5):601-614.e5.

36. Buijs N, Oosterink JE, Jessup M, et al. A new key player in VEGF-dependent angiogenesis in human hepatocellular carcinoma: dimethylarginine dimethylaminohydrolase 1. *Angiogenesis.* 2017;20(4):557–565.

37. Epstein FH, Moncada S, Higgs A. The L-Arginine-Nitric Oxide Pathway. *N. Engl. J. Med.* 1993;329(27):2002–2012.

38. Losordo DW, Dimmeler S. Therapeutic angiogenesis and vasculogenesis for ischemic disease: Part I: Angiogenic cytokines. *Circulation.* 2004;109(21):2487–2491.
39. Matsunaga T, Weihrauch DW, Moniz MC, et al. Angiostatin inhibits coronary angiogenesis during impaired production of nitric oxide. *Circulation*. 2002;105(18):2185–2191.

40. Jud P, Hafner F, Verheyen N, et al. Homoarginine/ADMA ratio and homoarginine/SDMA ratio as independent predictors of cardiovascular mortality and cardiovascular events in lower extremity arterial disease. *Sci. Rep.* 2018;8(1):1–7.

41. Phiri KS, Calis JCI, Faragher B, et al. Long term outcome of severe anaemia in Malawian children. *PLoS One*. 2008;3(8):e2903.

42. Opoka RO, Hamre KES, Brand N, et al. High postdischarge morbidity in Ugandan children with severe malarial anemia or cerebral malaria. *J. Pediatric Infect. Dis. Soc.* 2017;6(3):e41–e48.

43. Zucker JR, Lackritz EM, Ruebush TK, et al. Childhood mortality during and after hospitalization in western Kenya: Effect of malaria treatment regimens. *Am. J. Trop. Med. Hyg.* 1996;55(6):655–660.

44. Conroy AL, Hawkes M, McDonald CR, et al. Host biomarkers are associated with response to therapy and long-term mortality in pediatric severe malaria. *Open Forum Infect. Dis.* 2016;3(3):ofw134.

45. Patel H, Dunican C, Cunningham AJ. Predictors of outcome in childhood Plasmodium falciparum malaria. *Virulence*. 2020;11(1):199–221.

46. Weinberg JB, Yeo TW, Mukemba JP, et al. Dimethylarginines: Endogenous inhibitors of nitric oxide synthesis in children with falciparum malaria. *J. Infect. Dis.* 2014;210(6):913–922.

47. Chertow JH, Alkaitis MS, Nardone G, et al. Plasmodium Infection Is Associated with Impaired Hepatic Dimethylarginine Dimethylaminohydrolase Activity and Disruption of Nitric Oxide Synthase Inhibitor/Substrate Homeostasis. *PLoS Pathog.* 2015;11(9):e1005119.

48. Cichon B, Fabiansen C, Yaméogo CW, et al. Children with moderate acute malnutrition have inflammation not explained by maternal reports of illness and clinical symptoms: A cross-sectional study in Burkina Faso. *BMC Nutr.* 2016;2(57):1–10.

49. Opoka RO, Conroy AL, Waiswa A, et al. Severe anemia is associated with systemic inflammation in young children presenting to a tertiary hospital in Uganda. *Am. J. Trop. Med. Hyg.* 2020;103(6):2574–2580.

50. Kakande E, Greenhouse B, Bajunirwe F, et al. Associations between red blood cell variants and malaria among children and adults from three areas of Uganda: A prospective cohort study. *Malar. J.* 2020;19(1):1–9.

51. Mangano VD, Kabore Y, Bougouna EC, et al. Novel Insights into the Protective Role of Hemoglobin S and C Against Plasmodium falciparum Parasitemia. *J. Infect. Dis.* 2015;212(4):626–634.

52. Awotua-Efebo O, Alikor EA, Nkanginieme KE. Malaria parasite density and splenic status by ultrasonography in stable sickle-cell anaemia (HbSS) children. *Niger. J. Med.* 2004;13(1):40–43.

53. Agarwal A, Guindo A, Cissoko Y, et al. Hemoglobin C associated with protection from severe malaria in the Dogon of Mali, a West African population with a low prevalence of hemoglobin S. *Blood*. 2000;96(7):2358–2363.

54. Modiano D, Luoni G, Sirima BS, et al. Haemoglobin C protects against clinical Plasmodium falciparum malaria. *Nature*. 2001;414(6861):305–308.

55. Fairhurst RM, Fujioka H, Hayton K, Collins KF, Wellemes TE. Aberrant development of Plasmodium falciparum in hemoglobin CC red cells: Implications for the malaria protective effect of the homozygous state. *Blood*. 2003;101(8):3309–3315.
56. Fairhurst RM, Baruch DI, Brittain NJ, et al. Abnormal display of PfEMP-1 on erythrocytes carrying haemoglobin C may protect against malaria. *Nature*. 2005;435(7045):1117–1121.

57. Kilian N, Srismith S, Dittmer M, et al. Hemoglobin S and C affect protein export in Plasmodium falciparum-infected erythrocytes. *Biol. Open*. 2015;4(3):400–410.

58. Miller LH, Ackerman HC, Su XZ, Wellemes TE. Malaria biology and disease pathogenesis: Insights for new treatments. *Nat. Med.*. 2013;19(2):156–167.

59. Cholera R, Brittain NJ, Gillrie MR, et al. Impaired cytoadherence of Plasmodium falciparum-infected erythrocytes containing sickle hemoglobin. *Proc. Natl. Acad. Sci. U. S. A.*. 2008;105(3):991–996.

60. Fairhurst RM, Bess CD, Krause MA. Abnormal PfEMP1/knob display on Plasmodium falciparum-infected erythrocytes containing hemoglobin variants: Fresh insights into malaria pathogenesis and protection. *Microbes Infect.*. 2012;14(10):851–862.

61. Cyrklaff M, Sanchez CP, Kilian N, et al. Hemoglobins S and C interfere with actin remodeling in Plasmodium falciparum-infected erythrocytes. *Science (80-. ).* 2011;334(6060):1283–1286.

62. Beaudry JT, Krause MA, Diakite SAS, et al. Ex-Vivo cytoadherence phenotypes of Plasmodium falciparum strains from Malian children with hemoglobins A, S, and C. *PLoS One*. 2014;9(3):e92185.

63. Archer NM, Petersen N, Clark MA, et al. Resistance to Plasmodium falciparum in sickle cell trait erythrocytes is driven by oxygen-dependent growth inhibition. *Proc. Natl. Acad. Sci. U. S. A.*. 2018;115(28):7350–7355.

64. Lamonte G, Philip N, Reardon J, et al. Translocation of sickle cell erythrocyte MicroRNAs into Plasmodium falciparum inhibits parasite translation and contributes to malaria resistance. *Cell Host Microbe*. 2012;12(2):187–199.

65. Ferreira A, Marguti I, Bechmann I, et al. Sickle hemoglobin confers tolerance to plasmodium infection. *Cell*. 2011;145(3):398–409.

66. Shabani E. Identifying Parasite Virulence Factors and Host Genetic and Immunologic Factors that Contribute to Severe Malarial Outcomes in Ugandan Children. 2016;

67. Eleonore NLE, Cumber SN, Charlotte EE, et al. Malaria in patients with sickle cell anaemia: Burden, risk factors and outcome at the Laquintinie hospital, Cameroon. *BMC Infect. Dis.*. 2020;20(1):1–8.

68. Dondorp AM, Desakorn V, Pontavornpinyo W, et al. Estimation of the total parasite biomass in acute falciparum malaria from plasma PfHRP2. *PLoS Med.*. 2005;2(8):0788–0797.

69. Hendriksen ICE, Mwangi-Amumpaire J, von Seidlein L, et al. Diagnosing Severe Falciparum Malaria in Parasitaemic African Children: A Prospective Evaluation of Plasma PfHRP2 Measurement. *PLoS Med.*. 2012;9(8):e1001297.

70. Ochola LB, Siddondo BR, Ocholla H, et al. Specific receptor usage in Plasmodium falciparum cytoadherence is associated with disease outcome. *PLoS One*. 2011;6(3):e14741.

71. Newbold C, Warn P, Black G, et al. Receptor-specific adhesion and clinical disease in Plasmodium falciparum. *Am. J. Trop. Med. Hyg.*. 1997;57(4):389–398.

72. Turner GDH, Morrison H, Jones M, et al. An immunohistochemical study of the pathology of fatal malaria: Evidence for widespread endothelial activation and a potential role for intercellular adhesion molecule-1 in cerebral sequestration. *Am. J. Pathol.*. 1994;145(5):1057–1069.

73. Ouma BJ, Ssenkusu JM, Shabani E, et al. Endothelial Activation, Acute Kidney Injury, and Cognitive Impairment in Pediatric Severe Malaria. *Crit. Care Med.*. 2020;48(9):734–743.
74. Gramaglia I, Sobolewski P, Meays D, et al. Low nitric oxide bioavailability contributes to the genesis of experimental cerebral malaria. *Nat. Med.* 2006;12(12):1417–1422.

75. Yeo TW, Lampah DA, Tjitra E, et al. Increased asymmetric dimethylarginine in severe falciparum malaria: Association with impaired nitric oxide bioavailability and fatal outcome. *PLoS Pathog.* 2010;6(4):1–8.
Table 1. Clinical and demographic characteristics of children with severe anemia and *P. falciparum* parasitemia, by hemoglobin genotype.

|                                | HbSS (n = 22) | HbAA (n = 208) | P-valuea,b |
|--------------------------------|---------------|----------------|------------|
| **Baseline demographic characteristics** |               |                |            |
| Number of male patients (%)    | 13 (59.1)     | 127 (61.1)     | 0.86       |
| Median age (IQR), years        | 4.6 (3.7, 5.7) | 2.7 (2.0, 4.1) | <0.001     |
| Mean height-for-age z-score (±SD) | -0.51 ± 0.85 (n = 21) | -1.2 ± 1.4 (n = 205) | 0.03       |
| Mean weight-for-age z-score (±SD) | -1.0 ± 0.9    | -1.5 ± 1.1     | 0.04       |
| **Baseline clinical characteristics** |               |                |            |
| Median admission temperature (IQR), °C | 37.7 (37.0, 38.4) | 37.7 (36.8, 38.5) | 0.83       |
| Mean heart rate ± SD, beats per minute | 144 ± 23.7    | 149 ± 20.9     | 0.27       |
| Mean systolic blood pressure ± SD, mmHg | 95.2 ± 10.7   | 90.5 ± 13.3    | 0.05       |
| Mean diastolic blood pressure (IQR), mmHg | 56 (46, 66)   | 55 (45, 61)    | 0.51       |
| Mean respiratory rate ± SD, breaths per minute | 43.8 ± 13.7   | 45.8 ± 13.4 (n = 207) | 0.50       |
| Mean O₂ saturationc ± SD, % | 96.2 ± 2.6    | 96.4 ± 3.6 (n = 207) | 0.80       |
| Respiratory distressd (%) (95% CI) | 27.3 (8.7, 45.9) | 27.9 (21.7, 34.0) | 0.96       |
| Deep acidotic breathing (%) (95% CI) | 9.1 (0.0, 22) | 6.7 (3.3, 10)  | 0.70       |
| Capillary refill >2 seconds (%) (95% CI) | 9.1 (0.0, 22) | 19.7 (14.3, 25.2) | 0.22       |
| Palpable spleen (%)              | 11 (50.0)     | 136 (65.4)     | 0.15       |

Note: HbSS, hemoglobin SS; HbAA, hemoglobin AA; SD, standard deviation; IQR, interquartile range. For tests that did not include all participants, the n is listed below the result.

a. Determined by use of χ² for categorical data, student’s t test for parametric continuous data, and Wilcoxon rank-sum test for non-parametric continuous data, as appropriate.
b. P < 0.05 regarded as significant.
c. O₂ saturation is peripheral capillary oxygen saturation
d. Respiratory distress includes nasal flaring, intercostal recessions, chest indrawing, and/or deep acidotic breathing.
Table 2. Clinical laboratory values in children with severe anemia and *P. falciparum* parasitemia by sickle cell genotype

|                          | HbSS (n = 22) | HbAA (n = 208) | P-value<sup>a</sup>,<sup>b</sup> | β coefficient<sup>c,d</sup> (95% CI) | P-value<sup>b</sup> (adjusted for age) |
|--------------------------|---------------|----------------|---------------------------------|-------------------------------------|---------------------------------------|
| **Complete blood count (Mean ± SD)** |               |                |                                 |                                     |                                       |
| Hemoglobin, g/dL         | 3.7 (0.6)     | 3.7 (0.9)      | 0.71                            | -0.04 (-0.4, 0.4)                   | 0.85                                  |
| Hematocrit, %            | 12.5 (2.5)    | 13.7 (5.8)     | 0.35                            | -1.7 (-4.2, 0.9)                    | 0.21                                  |
| MCV, fl                  | 96.9 (11.7)   | 82.4 (10.3)    | <0.001                          | 14.4 (9.5, 19.2)                    | <0.001                                |
| RDW, %                   | 21.4 (5.17)   | 16.4 (3.7)     | <0.001                          | 6.2 (4.4, 7.9)                      | <0.001                                |
| WBC count, x10<sup>3</sup>/μL | 32.5 (16.0)  | 12.9 (8.2)     | <0.001                          | 20.1 (15.8, 24.5)                   | <0.001                                |
| % neutrophils            | 40.5 (12.8)   | 46.8 (13.7)    | 0.05                            | -9.2 (-15.5, -2.8)                  | 0.005                                 |
| % lymphocytes            | 48.7 (15.1)   | 41.0 (12.4)    | 0.01                            | 10.2 (4.2, 16.1)                    | 0.001                                 |
| % monocytes              | 8.7 (4.0)     | 10.4 (5.5)     | 0.16                            | -1.3 (-3.9, 1.3)                    | 0.32                                  |
| % basophils              | 1.7 (1.4)     | 1.2 (1.3)      | 0.14                            | 0.5 (-0.2, 1.2)                     | 0.18                                  |
| % eosinophils            | 1.3 (2.1)     | 1.1 (1.1)      | 0.48                            | 0.3 (-0.4, 1.0)                     | 0.39                                  |
| Platelet count, x10<sup>3</sup>/μL | 273 (203)  | 175 (126)      | 0.002                           | 86.7 (24.1, 149.4)                  | 0.007                                 |
| **Plasma markers of haemolysis (Median, IQR)** |               |                |                                 |                                     |                                       |
| LDH, U/L                 | 639 (469, 769)| 772 (639, 995) | 0.02                            | -0.1 (-0.2, -0.004)<sup>d</sup>     | 0.04                                  |
| Haptoglobin, mg/dL       | 0.1 (0.1, 0.1)| 0.1 (0.1, 0.1) | 0.64                            | 0.2 (-0.2, 0.4)<sup>d</sup>         | 0.52                                  |
| Total bilirubin, mg/dL   | 2.7 (1.6, 5)  | 1.2 (0.7, 1.9) | <0.001                          | 0.3 (0.2, 0.5)<sup>d</sup>          | <0.001                                |
| **Renal function (Median, IQR)** |               |                |                                 |                                     |                                       |
| Creatinine, mg/dL        | 0.35 (0.27, 0.43) | 0.35 (0.28, 0.47) | 0.73                            | -0.08 (-0.16, -0.004)<sup>d</sup>   | 0.04                                  |
| BUN, mg/dL               | 9.0 (7.0, 13) | 14 (9.0, 20)   | 0.007                           | -0.2 (-0.3, -0.1)<sup>d</sup>       | 0.001                                 |
| **Other clinical lab values (Median, IQR)** |               |                |                                 |                                     |                                       |
| Albumin, g/dL            | 3.3 (2.9, 3.5)| 2.6 (2.3, 2.9) | <0.001                          | 0.09 (0.05, 0.12)<sup>d</sup>       | <0.001                                |
| Lactate, mmol/L          | 3.9 (2.2, 7.0)| 5.0 (3.0, 8.3) | 0.21                            | -0.7 (-2.5, 1.0)                    | 0.43                                  |
| Blood culture positivity, n (%) | 1 (5.5)     | 22 (12.4)      | 0.64                            | -0.03 (-0.2, 0.1)                    | 0.75                                  |
| Stool helminthic infection, n (%) | 0 (0)        | 9 (6.8)        | 0.60                            | -0.08 (-0.2, 0.05)                   | 0.22                                  |
| HIV positivity, n (%)    | 0 (0)         | 6 (2.9)        | 1.0                             | -0.04 (-0.1, 0.04)                   | 0.33                                  |
|                       | Parasite density and PfHRP-2 concentration (Median, IQR) |                       |                       |               |
|-----------------------|----------------------------------------------------------|-----------------------|-----------------------|---------------|
|                       | Plasmodium falciparum HRP-2, ng/mL                        |                       |                       |               |
|                       | 197 (6, 469)                                              | 1050 (468, 2840)      | <0.001                | -1.0\(^d\) (-1.3, -0.6)\(^d\) | <0.001        |
| Parasite density in   | HRP-2, histidine-rich protein-2. For tests that did not  |                       |                       |               |
| peripheral blood,     | include all participants, the n is listed below the      |                       |                       |               |
| parasites x10\(^3\)/μL| result.                                                  |                       |                       |               |
|                       | 42 (3.0, 141)                                             | 50 (15, 230)          | 0.18                  | -0.3 (-0.7, 0.2)\(^d\) | 0.29          |
|                       | (n = 21)                                                  | (n = 205)             |                       |               |               |
| Estimated Parasite Biomass |                                              |                       |                       |               |
|                       | Circulating (x10\(^9\))                                  |                       |                       |               |
|                       | 60 (3.00, 189)                                            | 51 (14, 207)          | 0.42                  | -0.3 (-0.7, 0.2) | 0.31          |
|                       | (n = 21)                                                  | (n = 205)             |                       |               |               |
|                       | Sequestered (x10\(^9\))                                  |                       |                       |               |
|                       | 130 (0.00, 325)                                           | 731 (190, 1921)       | <0.001                | -0.5 (-0.9, -0.1) | 0.01          |
|                       | (n = 21)                                                  | (n = 202)             |                       |               |               |
|                       | Total (x10\(^9\))                                         |                       |                       |               |
|                       | 238 (6.00, 445)                                           | 835 (327, 2043)       | <0.001                | -0.6 (-0.9, -0.3) | <0.001        |
|                       | (n = 203)                                                 | (n = 203)             |                       |               |               |

**Note:** HbSS, hemoglobin SS; HbAA, hemoglobin AA; IQR, interquartile range; CI, confidence interval. HRP-2, histidine-rich protein-2. For tests that did not include all participants, the n is listed below the result.

- a. Determined by use of χ\(^2\) or Fisher Exact Test for categorical data where appropriate, student’s t test for parametric continuous data, and Wilcoxon rank-sum test for non-parametric continuous data, as appropriate.
- b. Significance determined with FDR = 0.05 correction for multiple comparisons.
- c. β coefficient of linear regression controlling for age
- d. Log10 transformed values used for linear regression
Table 3. Comparison of host immune and inflammatory response to *P. falciparum* in children with severe anemia and *P. falciparum* parasitemia by sickle cell genotype

| Cell biomarker | HbSS Median (IQR) | HbAA Median (IQR) | P-value<sup>a,b</sup> | β coefficient<sup>c</sup> (95% CI) | P-value<sup>b</sup> adjusted for age |
|---------------|-------------------|-------------------|------------------------|------------------------------------|----------------------------------|
| **Markers of inflammation** | | | | | |
| C-reactive protein, mg/dL | 25.0 (16.7, 34.5) (n = 22) | 44.0 (25.2, 64.7) (n = 192) | <0.001 | -0.2 (-0.4, 0.0) | 0.03 |
| Alpha-1 glycoprotein, mg/mL | 1350 (1048, 1887) (n = 19) | 2128 (1726, 2601) (n = 170) | <0.001 | -0.2 (-0.3, -0.1) | <0.001 |
| **Plasma concentrations of pro- and anti-inflammatory cytokines and chemokines** | | | | | |
| Granulocyte colony stimulating factor (G-CSF), pg/mL | 39.8 (17.3, 74.1) (n = 19) | 60.0 (37.4, 102.3) (n = 172) | 0.02 | -0.2 (-0.4, 0.0) | 0.10 |
| Interferon (IFN)-γ, pg/mL | 115 (67.9, 178) (n = 19) | 91.7 (57.5, 158) (n = 172) | 0.29 | 0.1 (-0.2, 0.3) | 0.60 |
| Interleukin (IL)-1β, pg/mL | 2.5 (0.5, 4.4) (n = 19) | 2.9 (1.9, 4.1) (n = 172) | 0.75 | -0.1 (-0.3, 0.1) | 0.38 |
| IL-1 receptor α, pg/mL | 506 (263, 811) (n = 19) | 607 (323, 1610) (n = 172) | 0.12 | -0.1 (-0.4, 0.1) | 0.40 |
| IL-4, pg/mL | 2.8 (1.3, 6.0) (n = 19) | 2.5 (1.1, 4.4) (n = 172) | 0.60 | 0.0 (-0.3, 0.3) | 0.96 |
| IL-6, pg/mL | 36.8 (5.4, 68.9) (n = 21) | 40.2 (13.7, 105) (n = 195) | 0.39 | -0.2 (-0.5, 0.2) | 0.36 |
| IL-8, pg/mL | 22.9 (15.8, 37.0) (n = 19) | 30.5 (19.8, 44.9) (n = 172) | 0.14 | -0.1 (-0.3, 0.1) | 0.29 |
| IL-10, pg/mL | 53.7 (16.2, 118) (n = 19) | 102 (35.3, 263) (n = 172) | 0.05 | -0.2 (-0.5, 0.2) | 0.27 |
| IL-12 p70, pg/mL | 17.5 (9.8, 26.3) (n = 19) | 22.2 (13.3, 35.8) (n = 172) | 0.11 | -0.1 (-0.4, 0.1) | 0.23 |
| **Monocyte Chemoattractant Protein (MCP)-1, pg/mL** | 15.4 (11.1, 25.8) (n = 19) | 33.4 (18.2, 87.9) (n = 172) | <0.001 | -0.4 (-0.7, -0.1) | 0.02 |
| **Macrophage Inflammatory Protein (MIP)-1α, pg/mL** | 6.7 (4.1, 11) (n = 19) | 6.4 (4.2, 10) (n = 172) | 0.90 | 0.0 (-0.3, 0.2) | 0.75 |
| MIP-1β, pg/mL | 181 (71.9, 313) (n = 19) | 285 (184, 425) (n = 172) | 0.004 | -0.2 (-0.4, -0.1) | <0.001 |
| **Platelet Factor 4 (platelet-free plasma), ng/mL** | 878 (381, 2100) (n = 19) | 709 (318, 1530) (n = 166) | 0.20 | 0.2 (-0.1, 0.5) | 0.14 |
| RANTES, pg/mL | 3790 (1530, 5470) (n = 19) | 3480 (1750, 6860) (n = 172) | 0.61 | -0.1 (-0.3, 0.1) | 0.48 |
| **Tumor Necrosis Factor (TNF)-α, pg/mL** | 41.7 (21.5, 64.1) (n = 21) | 87.6 (51.1, 141) (n = 195) | <0.001 | -0.3 (-0.6, -0.1) | 0.006 |
| **Plasma concentrations of markers of endothelial activation** | | | | | |
| Von Willebrand Factor, % of normal | 104 (72.6, 198) (n = 19) | 137 (69.2, 239) (n = 146) | 0.29 | -0.1 (-0.3, 0.1) | 0.41 |
| Soluble Vascular Cell Adhesion Molecule (sVCAM)-1, ng/mL | 3050 (2070, 5720) (n = 19) | 3260 (2550, 4800) (n = 171) | 0.51 | 0.0 (-0.1, 0.1) | 0.78 |
| Soluble Intracellular | 370 (230, 1230) | 727 (300, 1400) | 0.20 | 0.0 (-0.4, 0.3) | 0.84 |
### Plasma concentrations of markers of angiogenesis

| Adhesion Molecule          | (sICAM)-1, ng/mL | (n = 19) | (n = 172) | p-value | 95% CI       | FDR  |
|-----------------------------|------------------|----------|-----------|---------|--------------|------|
| sE-selectin, ng/mL         | 184 (117, 245)   | 190      | (135, 258)| 0.88    | 0.0 (-0.1, 0.1) | 0.54 |
| P-selectin, ng/mL          | 58.3 (47.9, 85.8)| 45.1     | (35.4, 66.3)| 0.22    | 0.1 (-0.1, 0.3) | 0.23 |
| Soluble Endothelial Protein C Receptor (sEPCR), ng/mL | 68.9 (60.1, 102) | 97.2     | (72.5, 250) | 0.02   | -0.1 (-0.2, 0.00) | 0.06 |

### Plasma concentrations of nitric oxide and regulators

| Nitric oxide (NO) concentration, µmol/L | 44.1 (31.4, 87.6) | 53.1 (31.7, 90.6) | 0.88 | 0.0 (-0.2, 0.2) | 0.59 |
|----------------------------------------|-------------------|-------------------|------|-----------------|------|
| Asymmetric Dimethylarginine (ADMA), µmol/L | 0.9 (0.7, 1.1)   | 0.7 (0.6, 0.9)    | 0.005 | 0.07 (0.0, 0.1) | 0.06 |
| L-arginine, µmol/L                     | 20 (20, 30)       | 30 (20, 30)       | 0.05 | -0.1 (-0.2, 0.0) | 0.007 |
| L-arginine:ADMA<sup>d</sup>            | 24.2 (21.6, 30.3) | 34.7 (25.9, 47.6) | 0.002 | -13.5 (-22.6, -4.4) | 0.004 |

### Note:
- HbSS, hemoglobin SS; HbAA, hemoglobin AA; IQR, interquartile range. For tests that did not include all participants, the n is listed below the result.
- a. Determined by use of Wilcoxon rank-sum test.
- b. Significant p-values in bold, determined by FDR = 0.05 correction for multiple comparisons.
- c. Denotes linear regression beta coefficient for log10-transformed values, adjusted for age.
- d. Denotes linear regression performed using non-transformed values.
Table 4. Association of markers of inflammation and endothelial activation associated with SCA and risk of readmission or death and risk of malarial outpatient visit within 24 months across all children with severe anemia and *P. falciparum* parasitemia

| Risk of Death or Readmission * | N obs, n event | HR | 95% CI  | P value b | HR | 95% CI  | P value b |
|-------------------------------|----------------|----|---------|-----------|----|---------|-----------|
| Angpt-2 (pg/mL)               | 186, 49        | 1.45 | 0.77, 2.72 | 0.25 | 1.48 | 0.75, 2.92 | 0.25 |
| TNFα (pg/mL)                  | 212, 57        | 0.54 | 0.36, 0.81 | **0.003** | 0.55 | 0.36, 0.83 | **0.004** |
| L-arg:ADMA ratio              | 165, 48        | 2.24 | 0.56, 8.91 | 0.25 | 2.67 | 0.64, 11.1 | 0.18 |

| Risk of Malaria Outpatient visit * | N obs, n event | HR | 95% CI  | P value b | HR | 95% CI  | P value b |
|------------------------------------|----------------|----|---------|-----------|----|---------|-----------|
| Angpt-2 (pg/mL)                    | 186, 81        | 1.83 | 1.09, 3.06 | 0.02 | 2.03 | 1.14, 3.59 | **0.016** |
| TNFα (pg/mL)                       | 212, 88        | 1.29 | 0.81, 2.06 | 0.28 | 1.33 | 0.82, 2.15 | 0.25 |
| L-arg:ADMA ratio                   | 165, 75        | 1.44 | 0.46, 4.47 | 0.53 | 1.77 | 0.55, 5.72 | 0.34 |

95% CI, 95% confidence interval

a. Cox regression is based on log10 transformation of biomarkers, so hazard ratio is increase in outcome for each log10 increase in biomarker

b. Significant p-values in bold, determined by FDR = 0.05